Novo Nordisk (NVO) faces a shareholder backlash as minority investors plan a protest vote against a board overhaul pushed by its dominant shareholder, the Novo Nordisk Foundation, Reuters’ Jacob Gronholt-Pedersen and Maggie Fick report. The Foundation, holding 77% of voting rights, aims to appoint its chairman, Lars Rebien Sorensen, as Novo’s new board chair to drive a more aggressive strategy in the obesity drug market amid intensifying competition from Eli Lilly (LLY), according to the report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo denies partnership with Mangoceuticals on obesity drug, Reuters says
- Eli Lilly says ‘no affiliation’ with Mangoceuticals
- Hims & Hers Stock (HIMS) Plunges despite New ‘Affordable’ Healthcare Platform
- Pfizer Stock (PFE) Rises as Metsera Shareholders Approve $10B Acquisition
- Mangoceuticals Stock (MGRX) Soars on Deal to Sell Obesity Drugs for Eli Lilly, Novo Nordisk